Scholarlink

<p>Congenital aortic valve regurgitation is seen in approximately 1 in 4,000 live-births globally. This study investigated the prevalence and early impacts of aortic regurgitation in a newborn cohort.&#xa0;Between April 2016 and October 2018, all newborns in the Copenhagen Area were offered systematic transthoracic echocardiography in a prospective, multicenter population-based study. Aortic valve function was categorized as no, trivial (glimpse of regurgitant flow and/or vena contracta &lt; 0.1&#xa0;cm), or non-trivial aortic regurgitation (vena contracta ≥ 0.1&#xa0;cm). Newborns with non-trivial regurgitation were matched 1:4 with controls (no regurgitation).&#xa0;Among 25,590 newborns, aortic regurgitation was detected in 329 newborns (52% male, median age 11 days), i.e. a prevalence of 1.3% (95% CI, 1.15%-1.43%), with 260 (79%) classified as trivial and 69 (21%) as non-trivial. Bicuspid aortic valve was more common in newborns with non-trivial regurgitation (13.0%) than controls (1.1%) (<i>p</i> &lt; 0.001). Newborns with non-trivial regurgitation had larger aortic dimensions compared to controls (mean ± SD): aortic valve annulus (7.3 ± 0.7&#xa0;mm vs. 7.0 ± 0.6&#xa0;mm), Sinuses of Valsalva (10.3 ± 1.0&#xa0;mm vs. 9.7 ± 1.0&#xa0;mm), sino-tubular junction (8.4 ± 0.8&#xa0;mm vs. 8.0 ± 0.8&#xa0;mm), and ascending aorta diameter (10.0 ± 0.9&#xa0;mm vs. 9.4 ± 1.1&#xa0;mm) (all <i>p</i> &lt; 0.006). Left ventricular dimensions and function did not differ between groups.&#xa0;Congenital aortic regurgitation was present in 1.3% of all newborns. Non-trivial regurgitation (0.3%) was associated with larger aortic dimensions and higher prevalence of bicuspid aortic valve (13%), but no early signs of left ventricular impairment. Follow-up will help identify those at risk of progression, potentially due to valvular and/or aortic pathology, who may benefit from regular surveillance, and those who can be safely discontinued.</p><p><i>Trial registration</i>&#xa0;ClinicalTrials.gov NCT02753348 (registered April 27th 2016).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prevalence of Congenital Aortic Valve Regurgitation in a Newborn Cohort

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月20日

查看全文
  • Aysha F. Farooqui,
  • Jakob B. Norsk,
  • Anna A. Raja,
  • Vibeke Hjortdal,
  • Julian K. Bjerrekaer,
  • Marie Reindahl Fagerlund,
  • R. Ottilia Vøgg,
  • Christian Pihl,
  • Henning Bundgaard,
  • Kasper Iversen,
  • Anne-Sophie Sillesen

摘要

Congenital aortic valve regurgitation is seen in approximately 1 in 4,000 live-births globally. This study investigated the prevalence and early impacts of aortic regurgitation in a newborn cohort. Between April 2016 and October 2018, all newborns in the Copenhagen Area were offered systematic transthoracic echocardiography in a prospective, multicenter population-based study. Aortic valve function was categorized as no, trivial (glimpse of regurgitant flow and/or vena contracta < 0.1 cm), or non-trivial aortic regurgitation (vena contracta ≥ 0.1 cm). Newborns with non-trivial regurgitation were matched 1:4 with controls (no regurgitation). Among 25,590 newborns, aortic regurgitation was detected in 329 newborns (52% male, median age 11 days), i.e. a prevalence of 1.3% (95% CI, 1.15%-1.43%), with 260 (79%) classified as trivial and 69 (21%) as non-trivial. Bicuspid aortic valve was more common in newborns with non-trivial regurgitation (13.0%) than controls (1.1%) (p < 0.001). Newborns with non-trivial regurgitation had larger aortic dimensions compared to controls (mean ± SD): aortic valve annulus (7.3 ± 0.7 mm vs. 7.0 ± 0.6 mm), Sinuses of Valsalva (10.3 ± 1.0 mm vs. 9.7 ± 1.0 mm), sino-tubular junction (8.4 ± 0.8 mm vs. 8.0 ± 0.8 mm), and ascending aorta diameter (10.0 ± 0.9 mm vs. 9.4 ± 1.1 mm) (all p < 0.006). Left ventricular dimensions and function did not differ between groups. Congenital aortic regurgitation was present in 1.3% of all newborns. Non-trivial regurgitation (0.3%) was associated with larger aortic dimensions and higher prevalence of bicuspid aortic valve (13%), but no early signs of left ventricular impairment. Follow-up will help identify those at risk of progression, potentially due to valvular and/or aortic pathology, who may benefit from regular surveillance, and those who can be safely discontinued.

Trial registration ClinicalTrials.gov NCT02753348 (registered April 27th 2016).